“In 2008, the FDA banned the company from importing about 30 drugs after it found manufacturing deficiencies at two of the company's facilities in India, and Ranbaxy was later accused of falsifying data used in drug applications. Ranbaxy agreed to engage a third party to conduct a review of its facilities, implement procedures to ensure data integrity in its marketing applications, and ensure it meets good manufacturing practices.” In the last years it has been that criticism has been brought upon the FDA for being too easygoing with certain manufacturers.   Some may say that good things about the FDA for catching this particular problem before people got hurt.   With the FDA knowing how poor Ranbaxy’s history has been and still approving the Ranbaxy’s Lipitor; judgment is brought upon the FDA.  We basically don’t know if the FDA was being pressured the drug companies, to get an instant approval to this Lipitor to be distributed to the public.  One thing we’re sure of is that that the inspection towards future approvals increases each time the FDA has a high profile recall like the generic Lipitor, which we can all agree that this matter is good for the public.  Catching these problems is good because more thorough inspections are conducted to come up with the decision of the problem even happened in the first place. The rational conclusion for a monitoring process in catching such problems seems to be getting much better.   But ultimately the goal is to catch these issues before the product is in consumers’ hands and bodies.